GLAXOSMITHKLINE PLC Form 6-K July 28, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 28 July 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

1. Details of PDMR/person closely associa	ated with them ('PCA')	
a) Name	Sir Andrew Witty	
b)Position/status	CEO	
c) Initial notification/ amendment	Initial notification	
$_{2}$ Details of the issuer, emission allowance market participant, auction		
² . platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b)LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to be repeated for (i) each type of		
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
place where transaction(s) has been conducted		
	Ordinary shares of 25 pence	
	each ('Ordinary Shares')	
a) Description of the financial instrument	ISIN: GB0009252882	

b)Nature of the transaction

c) Price(s) and volume(s)

27 July 2016 at a price of £16.9350. Price(s) Volume(s) £16.9350 10,000 n/a (single transaction)

Sale of Ordinary Shares on

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction	2016-07-27
f Place of the transaction	London Stock Exchange
1)	(XLON)

1. Details of PDMR/person closely asso	ciated with them ('PCA')	
a) Name	Mr D S Redfern	
b)Position/status	Chief Strategy Officer	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
² . platform, auctioneer or auction monit	or	
a) Name	GlaxoSmithKline plc	
b)LEI	5493000HZTVUYLO1D793	

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

	Ordinary shares of 25 pence
	each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882

b)Nature of the transaction	The exercise of options over 26,800 Ordinary Shares, granted on 20 February 2007 under the GlaxoSmithKline Share Option Plan.
c) Price(s) and volume(s)	Price(s) £14.88 26,800 n/a (single transaction)
Aggregated information d) Aggregated volume Price	
e) Date of the transaction Place of the transaction f)	2016-07-27 n/a
 Details of PDMR/person closely assoc a) Name b) Position/status c) Initial notification/ amendment Details of the issuer, emission allowan platform, auctioneer or auction monito a) Name 	Mr D S Redfern Chief Strategy Officer Initial notification ce market participant, auction

b)LEI 5493000HZTVUYL01D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882

b)Nature of the transaction c)Nature of the transaction c)

g		
c) Price(s) and	Price(s)	Volume(s)
volume(s)	£16.942	26,800
	n/a (single	transaction)
Aggregated information d) Aggregated volume Price		
e) Date of the transaction Place of the transaction f)	2016-07-2 London St (XLON)	7 ock Exchange
1. Details of PDMR/person closely associ	ated with the	em ('PCA')
a) Name	Mr D S Re	
h)Position/status	Chief Strat	tegy Officer
Initial notification/	Initial noti	fication
amenument		
2. Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market pa	rticipant, auction
a) Name		thKline plc
b)LEI		ZTVUYLO1D793
Details of the transaction(s): section to		
3. instrument; (ii) each type of transaction	-	
place where transaction(s) has been con		
	Ordinary s	hares of 25 pence
		inary Shares')
a) Description of the financial instrument	ISIN: GB0	0009252882
b)Nature of the transaction	24,186 Ord granted on	se of options over dinary Shares, 19 February 2008 GlaxoSmithKline
	Share Opti	
	-	
c) Price(s) and	Price(s)	Volume(s)
volume(s)	£11.47	24,186
	n/a (single	transaction)
Aggregated information d)		
Aggregated volume Price		
Appropried Volume Fried		
e) Date of the transaction	2016-07-2	7
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associa	ted with them ('PCA')	
a) Name	Mr D S Redfern	
b)Position/status	Chief Strategy Officer	
c) Initial notification/ amendment	Initial notification	
$_{2}$ Details of the issuer, emission allowance market participant, auction		
² platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b)LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to be repeated for (i) each type of		
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
place where transaction(s) has been cond	ducted	
	Ordinary shares of 25 pence	
	each ('Ordinary Shares')	
a) Description of the financial instrument	ISIN: GB0009252882	

The sale	of 24,186 Ordinary
Shares for	ollowing the
exercise	of options granted
h) Notice of the transaction on grante	ed on 19 February
b)Nature of the transaction 2008 und	ler the
GlaxoSn	nithKline Share
Option P	'lan.
-	

Price(s) and	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.938	24,186
Aggregated information	n/a (single	transaction)
d)		

Aggregated volume Price

e) Date of the transaction	2016-07-27
$f_{\rm f}$ Place of the transaction	London Stock Exchange
1)	(XLON)

1. Details of PDMR/person closely associa	tted with them ('PCA')	
a) Name	Mr D S Redfern	
b)Position/status	Chief Strategy Officer	
c) Initial notification/ amendment	Initial notification	
2 Details of the issuer, emission allowance market participant, auction		
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b)LEI	5493000HZTVUYLO1D793	
3.		

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument ISIN: GB0009252882

	The exercise of options over	
b)Nature of the transaction	2,614 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline	
	Share Option Plan.	
c) Price(s) and volume(s)	Price(s) Volume(s)	
volume(s)	£11.47 2,614 n/a (single transaction)	
Aggregated information d)	iva (single transaction)	
Aggregated volume Price		
e) Date of the transaction	2016-07-28	
f) Place of the transaction	n/a	
1. Details of PDMR/person closely associa	ated with them ('PCA')	
a) Name	Mr D S Redfern	
b)Position/status	Chief Strategy Officer	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction	
a) Name	GlaxoSmithKline plc	
b)LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to be repeated for (i) each type of		
3. instrument; (ii) each type of transaction		
place where transaction(s) has been con	Ordinary shares of 25 pence	
	each ('Ordinary Shares')	
a) Description of the financial instrument	each (Orumary Shares)	
a) Description of the financial instrument	ISIN: GB0009252882	
a) Description of the financial instrument	•	
a) Description of the financial instrument	ISIN: GB0009252882 The sale of 2,614 Ordinary	
a) Description of the financial instrument	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the	
a) Description of the financial instrument	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the exercise of options granted	
b)Nature of the transaction	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February	
	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the exercise of options granted	
	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the	
	ISIN: GB0009252882 The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share	

c) Price(s) and volume(s)

£17.035

Aggregated information d) Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2016-07-28
Place of the transaction	London Stock Exchange
f)	(XLON)

1. Details of PDMR/person closely associated with them ('PCA')			
a) Name	Ms C Thomas		
b)Position/status	Senior Vice President, Human Resources		
c) Initial notification/ amendment	Initial notification		
2. Details of the issuer, emission allowance market participant, auction			
² . platform, auctioneer or auction monitor			
a) Name	GlaxoSmithKline plc		
b)LEI	5493000HZTVUYLO1D793		
Details of the transaction(s): section to be repeated for (i) each type of			
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
-	Ordinary shares of 25 pence each ('Ordinary Shares')		
a) Description of the financial instrument	ISIN: GB0009252882		

b)Nature of the	transaction
-----------------	-------------

Price	Price(s) and
0)	volume(s)

28 July 2016 at a price of £16.9757. Price(s) Volume(s)

Sale of Ordinary Shares on

Price(s) and	Price(s)	volume(s)
c) Price(s) and volume(s)	£16.9757	43,000
	n/a (single transaction)	

Aggregated information d)

Aggregated volume Price

e) Date of the transaction f) Place of the transaction 2016-07-28 London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: July 28, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc